Navigation Links
A Novel Target for Type-2 Diabetes Atk2

Researchers at the University of Pennsylvania School of Medicine have discovered a potential new target for treating type 2 diabetes The target is a protein, along with its molecular partner, that regulates fat metabolism.

Over the last 10 years, we have begun to understand the importance of fat metabolism in diabetes, notes lead author Morris J. Birnbaum, MD, PhD, the Willard and Rhoda Ware Professor of Diabetes and Metabolic Diseases at Penn and an Investigator of the Howard Hughes Medical Institute.

Type 2 diabetics are at a higher risk for cardiovascular disease because they also have disorders in fat metabolism as a result of obesity and abnormal insulin action. Birnbaum is also the Associate Director of the Type 2 Diabetes Unit for Penns Institute for Diabetes, Obesity, and Metabolism.

When a person eats a meal, the pancreas usually responds by secreting insulin that signals the liver to stop making glucose and burning fat. When a type 2 diabetic eats a meal, insulin cannot stop the manufacture of glucose in the liver, but it can stop the burning of fat stores. This gives the diabetic person a double whammy: fatty acids accumulate from food and from the liver. Consequently, more fat is deposited in tissues and obesity worsens.

Until now there was no clear connection between insulin and the control of fat metabolism. This study shows that when insulin is present, as it is after a meal, the protein Akt2/PKB adds a phosphate group to its molecular partner PGC-1a. When this happens, PGC-1a cannot activate the genes needed for fat metabolism.

The findings suggest that if a drug could induce Akt2/PKB to add the phosphate group (phosphorylation) to PGC-1a, then the liver of a diabetic might be fooled into stopping the oxidation of fat stores. Muscle and fat tissue also burn fat stores, and we are currently investigating whether PGC-1a and Akt2/PKB have the same role in those tissues, says Birnbaum.

The researchers also found that insulin-stimulated phosphorylation of PGC-1a was blunted in mice that had non-functional Akt2/PKB. Finally, they showed that livers with too much PGC-1a or with PGC-1a that could not be phosphorylated put out many copies of the genes for fat metabolism. Each approach pointed to the same conclusion: PGC-1a had phosphate groups added to it by Akt2/PKB in the presence of insulin and this prevented the turning on of genes that make fat.

There are currently no drugs that target PGC-1a and Akt2/PKB. We hope that drug companies will look for new ways to modify fat metabolism in type 2 diabetics using these possible targets, says Birnbaum.


'"/>




Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2017)... Dallas, TX (PRWEB) , ... ... ... HCC Risk Adjustment solution leverages advanced data analytics to accurately understand each ... ensure proper reimbursement for a given population. This new solution helps transform ...
(Date:2/22/2017)... ... February 22, 2017 , ... Sideline Products participated in the World ... TV host Tom Seay and his production crew. Tom Seay’s program “Best of ... the world. Saddle Sidekicks will be featured on April 6, 2017. After the ...
(Date:2/22/2017)... ... February 22, 2017 , ... ANGLESTRONG , the new recovery management app ... the App Store and Google Play . Florida-based Sober Network, Inc., ... recovery industry, partnered with Angle to build ANGLESTRONG. The new recovery management app is ...
(Date:2/22/2017)... ... ... A product of digesting a micronutrient found in soy may hold the key ... while others do not, a University of Pittsburgh Graduate School of Public Health-led study ... some types of “good” gut bacteria when they metabolize isoflavones (micronutrients found in dietary ...
(Date:2/22/2017)... ... 22, 2017 , ... Super-Sod will attend the Athens Home Show with a ... A shift from Super-Sod’s simple Athens Home Show booth of 2016, this year’s exhibit ... plant manager Chris Roquemore constructed furniture from recycled pallet wood at the Super-Sod farm ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... and PUNE, India , February 22, 2017 ... Market Research, titled, "Automated Radio Synthesis Modules Market: Global Opportunity ... radiosynthesis modules market was worth $20 million in 2015 and ... CAGR of 6.6% from 2016 to 2022. North ... of both market revenues and unit volumes, whereas ...
(Date:2/22/2017)... , Feb 22, 2017 Research and ... Drugs Market by Drug Molecule (Biologic, Small Molecule Drugs), By ... Inhibitors, Interleukin Blockers) Outlook 2022" report to their offering. ... The ... growth during 2016-2022 This report provides a detailed ...
(Date:2/22/2017)... , Feb. 22, 2017 The Senior Care ... U.S. Senate and House of Representatives that will curtail ... Managers (PBMs) -- from extracting retroactive direct and indirect ... care (LTC) pharmacies and the Medicare program. ... (R-WV) and Jon Tester (D-MT), and ...
Breaking Medicine Technology: